Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.
Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.
Carlos de Sousa
CEO
Gustav Gaudernack
CSO
Hans Vassgård Eid
CFO
Jens Bjørheim
CMO
Ton Berkien
CBO
Forecast net cash (NOKm)
346.1
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | (35.0) | (27.0) | 10.8 |
Relative | (35.0) | (23.5) | 20.7 |
52 week high/low | NOK136.0/NOK59.9 |
Ultimovacs is a biotechnology company focused on developing a next generation cancer vaccine with virtually universal potential. Lead asset, UV1, activates the immune system to recognise cancer cells that express hTERT, which is present in c 85% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. The company’s R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The broad R&D programme includes five Phase II trials in different solid tumours, which will enrol more than 600 patients in total. Readouts are expected over 2023–25. The most near-term catalysts for the share price are top-line readouts from the Phase II NIPU trial in pleural mesothelioma and the Phase II INITIUM study in malignant melanoma expected in H123 and H223, respectively.
Y/E Dec | Revenue (NOKm) | EBITDA (NOKm) | PBT (NOKm) | EPS (fd) (öre) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2021A | 0.0 | (161.1) | (164.7) | (508.83) | N/A | N/A |
2022A | 0.0 | (181.0) | (167.8) | (489.06) | N/A | N/A |
2023E | 0.0 | (222.7) | (210.8) | (612.84) | N/A | N/A |
2024E | 0.0 | (274.0) | (277.9) | (807.97) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.